Represents the royalties to be received by the entity from the other party, expressed as a percentage of net sales.

No definition available.

Name:	tbph_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSales
Namespace Prefix:	tbph_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the potential future contingent payments that the entity is eligible to receive.

+ References

No definition available.

+ Details

Name:	tbph_CollaborativeArrangementContingentPaymentThatEntityCouldEarn
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of required upfront payment to be received under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	tbph_CollaborativeArrangementRequiredUpfrontPayment
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned under collaborative arrangements from upfront payments and contingent payments.

+ References

No definition available.

+ Details

Name:	tbph_CollaborativeArrangementsRevenue
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the regulatory milestone payment the entity will be receiving.

+ References

No definition available.

+ Details

Name:	tbph_RegulatoryMilestonePaymentReceivable
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Required potential milestones receivable for development, regulatory and commercial launch milestones.

+ References

No definition available.

+ Details

Name:	tbph_RequiredPotentialMilestonesReceivableForDevelopmentRegulatoryAndCommercialLaunchMilestones
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=tbph_TakedaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=tbph_AlfaWassermannMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements - Takeda & Wassermann Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Collaborative Arrangements
Revenue from collaborative arrangements		$ 31,045	$ 32,718	$ 7,270
Takeda Pharmaceuticals
Collaborative Arrangements
Revenue from collaborative arrangements		15,075	$ 0	$ 0
Alfa Wassermann
Collaborative Arrangements
Collaborative Arrangement Contingent Payment that Entity could Earn		10,000
Regulatory Milestone Payment Receivable		$ 53,500
Alfa Wassermann \| Maximum
Collaborative Arrangements
Collaborative Arrangement Annual Royalties as Percentage of Net Sales		20.00%
Takeda Collaborative Arrangement
Collaborative Arrangements
Required upfront payment	$ 15,000
Potential milestones associated with development, regulatory and commercial launch milestones for EFI	$ 110,000